327030-39-7

Basic information

• Product Name: 4-(3-BROMO-PHENYL)-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER
• Synonyms: 4-(3-BROMO-PHENYL)-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER;1-BOC-4-(3-Bromophenyl)piperazine;1-Piperazinecarboxylic acid, 4-(3-bromophenyl)-, 1,1-dimethylethyl ester;t-Butyl 4-(3-Bromophenyl)piperazine-1-carboxylate;tert-Butyl 4-(3-broMophenyl)piperazine-1-carboxylate;tert-Butyl 4-(3-bromophenyl)piperazine-1-carboxylate, 4-(3-Bromophenyl)-1-(tert-butoxycarbonyl)piperazine, 1-Bromo-3-[4-(tert-butoxycarbonyl)piperazin-1-yl]benzene
• CAS NO: 327030-39-7
• Molecular Formula: C₁₅H₂₁BrN₂O₂
• Molecular Weight: 341.24
• Product Categories: Aryl;Organohalides
• Mol File: 327030-39-7.mol

Chemical Properties

• Boiling Point: 424.6±40.0 °C(Predicted)
• Appearance: /
• Density: 1.332±0.06 g/cm3(Predicted)
• PKA: 2.12±0.20(Predicted)
• CAS DataBase Reference: 4-(3-BROMO-PHENYL)-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(3-BROMO-PHENYL)-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(327030-39-7)
• EPA Substance Registry System: 4-(3-BROMO-PHENYL)-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(327030-39-7)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 327030-39-7(Hazardous Substances Data)

Usage

Uses

Used in Medicinal Chemistry:
4-(3-Bromo-phenyl)-piperazine-1-carboxylic acid tert-butyl ester is used as a building block for the synthesis of various pharmaceutical compounds. Its unique structure and functional groups make it a valuable intermediate in the development of potential drug candidates.
Used in Drug Discovery:
In the field of drug discovery, 4-(3-Bromo-phenyl)-piperazine-1-carboxylic acid tert-butyl ester is employed as a key intermediate for the creation of new drug molecules. Its versatility allows for the exploration of different chemical modifications to enhance the therapeutic potential of resulting compounds.
Used in Organic Synthesis:
4-(3-Bromo-phenyl)-piperazine-1-carboxylic acid tert-butyl ester is used as a versatile intermediate in organic synthesis, enabling the development of a variety of organic compounds with potential applications in various industries.
Used in Material Science:
In material science, 4-(3-Bromo-phenyl)-piperazine-1-carboxylic acid tert-butyl ester may have potential applications due to its unique structural features, contributing to the advancement of new materials with specific properties for various uses.

Upstream product

• 108-36-1 1,3-dibromobenzene 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 31197-30-5 1-(3-bromophenyl)piperazine 
• 591-18-4 1-Bromo-3-iodobenzene 

Downstream Products

• 1240255-73-5 C₁₉H₂₄N₂O₂S 
• 540752-87-2 tert-butyl 4-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]piperazine-1-carboxylate 
• 1370453-96-5 N-[6-(3-piperazin-1-ylphenyl)pyridin-2-yl]-4-(trifluoromethyl)pyridin-2-amine 
• 1370454-38-8 N-[6-(3-piperazin-1-ylphenyl)pyridin-2-yl]pyrazin-2-amine 
• 1370454-40-2 tert-butyl 4-{3-[6-(pyrazin-2-ylamino)pyridin-2-yl]phenyl}piperazine-1-carboxylate 
• 807624-20-0 1,1-dimethylethyl 4-(3-cyanophenyl)piperazine-1-carboxylate 
• 937048-39-0 3‐({4‐[(tert-butoxy)carbonyl]piperazin‐1‐yl}phenyl)boronic acid 
• 951626-85-0 tert-butyl 4-(3-fluorophenyl)piperazine-1-carboxylate 
• 935759-91-4 4-oxo-N-({3-[4-(1H-tetrazol-5-ylacetyl)piperazin-1-yl]phenyl}methyl)-3,4-dihydroquinazoline-2-carboxamide 
• 935759-89-0 N-({3-[4-(1H-imidazol-4-ylacetyl)piperazin-1-yl]phenyl}methyl)-4-oxo-3,4-dihydroquinazoline-2-carboxamide 
• 935759-88-9 4-oxo-N-[(3-{4-[(5-oxo-2,5-dihydro-1H-pyrazol-3-yl)acetyl]piperazin-1-yl}phenyl)methyl]-3,4-dihydroquinazoline-2-carboxamide 
• 935759-87-8 4-oxo-N-[(3-{4-[(5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)acetyl]piperazin-1-yl}phenyl)methyl]-3,4-dihydroquinazoline-2-carboxamide 
• 935759-86-7 N-[(3-{4-[(2,5-dioxoimidazolidin-4-yl)acetyl]piperazin-1-yl}phenyl)methyl]-4-oxo-3,4-dihydroquinazoline-2-carboxamide 

Relevant articles and documents

Transition Metal-Free Synthesis of meta-Bromo- and meta-Trifluoromethylanilines from Cyclopentanones by a Cascade Reaction

Anilines are key constituents in biologically active compounds and often obtained from transition metal-catalyzed coupling of an aryl halide with an amine. In this work, we report a transition metal-free method for the synthesis of meta-bromo- and meta-trifluoromethylanilines starting from 3-tribromomethylcyclopentanone or 3-(2-bromo-2-chloro-1,1,1-trifluoroethyl)cyclopentanone, respectively. The scope of the transformation is shown by application of primary, secondary and aromatic amines. The reaction proceeds in acceptable to high yields (20–81 %), and allows for the synthesis of anilines with substitution patterns otherwise difficult to access.

MONOACYLGLYCEROL LIPASE INHIBITORS

Provided are compounds of formula (I), or a pharmaceutically acceptable salt or solvate thereof: Also provided are compositions comprising compounds of formula (I). The compounds and compositions are also provided for use as medicaments, for example as medicaments useful in the treatment of a condition modulated by monoacylglycerol lipase (MAGL). Also provided are the use of compounds and compositions for the inhibition of monoacylglycerol lipase (MAGL).

Receptor-interacting protein kinase 2 (RIPK2) and nucleotide-binding oligomerization domain (NOD) cell signaling inhibitors based on a 3,5-diphenyl-2-aminopyridine scaffold

Receptor-interacting protein kinase 2 (RIPK2) is a key mediator of nucleotide-binding oligomerization domain (NOD) cell signaling that has been implicated in various chronic inflammatory conditions. A new class of RIPK2 kinase/NOD signaling inhibitors bas

COMPOSITIONS FOR USE IN METHODS OF INHIBITING PROTEIN KINASES

Identified compounds demonstrate protein kinase inhibitory activity and inhibition of dependent cell signaling pathways, such as NOD2 cell signaling. More specifically, the compounds are demonstrated to inhibit receptor interacting kinase 2 (RIPK2) and/or Activin- like kinase 2 (ALK2). Compounds that are either dual RIPK2/ALK2 inhibitors or that preferentially inhibit RIPK2 or ALK2 could provide therapeutic benefit.

Discovery of 7-(3-(piperazin-1-yl)phenyl)pyrrolo[2,1-f][1,2,4]triazin-4-amine derivatives as highly potent and selective PI3Kδ inhibitors

As demonstrated in preclinical animal models, the disruption of PI3Kδ expression or its activity leads to a decrease in inflammatory and immune responses. Therefore, inhibition of PI3Kδ may provide an alternative treatment for autoimmune diseases, such as RA, SLE, and respiratory ailments. Herein, we disclose the identification of 7-(3-(piperazin-1-yl)phenyl)pyrrolo[2,1-f][1,2,4]triazin-4-amine derivatives as highly potent, selective and orally bioavailable PI3Kδ inhibitors. The lead compound demonstrated efficacy in an in vivo mouse KLH model.

Design, synthesis, and biological activity of novel, potent, and highly selective fused pyrimidine-2-carboxamide-4-one-based matrix metalloproteinase (MMP)-13 zinc-binding inhibitors

Matrix metalloproteinase-13 (MMP-13), a member of the collagenase family of enzymes, has been implicated to play a key role in the pathology of osteoarthritis. Recently, we have reported the discovery of a series of quinazoline-2-carboxamide based non-zin

USP7 INHIBITOR COMPOUNDS AND METHODS OF USE

2-Aminopyridine compounds of Formula I are provided, and various substituents including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for modulating USP7, and for treating cancer and immune disorders such as inflammation mediated by USP7. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

BICYCLIC HETEROARYL AMINE COMPOUNDS AS PI3K INHIBITORS

Disclosed are compounds of Formula (I) or a salt thereof; wherein: X is N or CH; Q1 is: (i) C1, Br, I, -CN, -CH3, or -CF3; (ii) a 5-membered heteroaryl selected from pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, and thiadiazolyl; (iii) a 6?membered heteroaryl selected from pyridinyl, pyridazinyl, and pyrimidinyl; or (iv) a bicyclic heteroaryl selected from indolyl, pyrrolopyridinyl, pyrazolopyridinyl and benzo[d]oxazolyl; wherein each of said 5-membered, 6-membered, and bicyclic heteroaryl is substituted with zero to 1 Ra and zero to 1 Rb; and R1, R2, R3, R4, R5, R6, Ra, and Rb are defined herein. Also disclosed are methods of using such compounds as modulators of PI3K, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases.

CaMKII INHIBITORS AND USES THEREOF

The present invention provides compounds useful as inhibitors of Ca2+/calmodulindependent protein kinase (CaMKII), compositions thereof, and methods of using the same. Cardiovascular disease remains the number one cause of death in developed countries. Furthermore, incidence of cardiovascular disease has increased dramatically in developing countries. Although cardiovascular disease usually affects older adults, the antecedents of cardiovascular disease, notably atherosclerosis, begin in early life, making primary prevention efforts necessary from childhood.

Highly potent aminopyridines as Syk kinase inhibitors

A novel class of potent Syk inhibitors has been developed from rational design. Highly potent aminopyridine derivatives bearing a 4-trifluoromethyl-2- pyridyl motif and represented by compound 13b IC50: 0.6 nM were identified. Substitution by a 2-pyrazinyl motif and SAR expansion in position 4 of the central core provided diverse potent non-cytotoxic Syk inhibitors showing nanomolar activity inhibiting human mast cell line LAD2 degranulation.